DR.-REDDY'S
1.4.2022 14:02:03 CEST | Business Wire | Press release
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and MediCane Health Inc. (along with its subsidiaries together referred to as "MediCane") today announced the launch of its medical cannabis product in Germany.
As part of a collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support. As the exclusive distributor of the products in Germany, Dr. Reddy's will provide access to MediCane's medical cannabis products under its own brand supported by a specialized field force that can provide education on the use of the products and guidance on the health insurance reimbursement process to healthcare professionals.
The launch marks MediCane's entry into the pharmaceutical sector of a major European market. For Dr. Reddy's, the launch reinforces its presence in Germany's growing medical cannabis market, building on its recent acquisition of Nimbus Health GmbH that specializes in the distribution, registration, sales and marketing of medical cannabis.
With over 83 million inhabitants benefitting from broad access to healthcare services, Germany already represents more than half of the current European Union medical cannabis market, thanks to developed regulations and reimbursement from sick-funds to medical cannabis under certain circumstances1 . The demand for medical cannabis has increased over the past years, driven by the German Parliament's (Bundestag) legalization of medical cannabis in 2017. The medical cannabis market in Germany is valued at ~122 Mio. € with growth of ~25% in 2021 compared to 2020 and a CAGR of ~55 % since 2017. Around 150,000 German patients benefit from medical cannabis for their otherwise unmet health needs2 , according to the reports3 especially in the area of pain management, spasticity, anorexia, vomiting, depression.
Dr. Reddy's and MediCane have also signed an agreement for the co-funding of a phase II clinical trial for a cannabis product aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD). Dr. Reddy's will hold exclusive sales and marketing rights for such product in Europe (except Russia and CIS countries) upon completion of such trial. The parties expect to commence the clinical trial of the product during the second half of 2022. BPSD refers to the spectrum of commonly observed non-cognitive and non-neurological symptoms of dementia, such as agitation, aggression, psychosis, depression, and apathy.
Patrick Aghanian, Head of European Generics, Dr. Reddy's, said: "This collaboration with MediCane Health demonstrates Dr. Reddy's commitment to take a leadership position in Europe's rapidly growing medical cannabis market. With MediCane, we join forces with a unique and differentiated research-based partner in the medical cannabis field. We are very pleased about the strategic, multi-dimensional collaboration with MediCane, which further complements our mission to accelerate access to medical cannabis to meet unmet patient needs and improve the quality of life of patients."
Yossi BenAmram, co-founder and Group CEO, MediCane, said: "This collaboration articulates MediCane's strategy to develop evidence-based medical products and partnering with leading pharmaceutical companies to maximize the potential of these drugs for patients. This collaboration is a very important step for MediCane, for the short, medium and long term and we couldn't be more excited to partner with a reputable and resourceful company like Dr. Reddy's. With MediCane's agrotechnical and biological cannabis-specific R&D resources and know-how, and Dr. Reddy's proven sales, marketing and distribution capabilities, with wide geographic access in line with our strategy, as well as powerful regulatory and R&D capabilities for generic drug development, I believe this synergistic partnership can be at the forefront of the European medical cannabis market makers in the foreseeable future.”
About Dr. Reddy's Laboratories :
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
About MediCane Health Inc. :
Founded in 2019, MediCane's seed-to-costumer business model allows comprehensive monitoring and control of the cultivation process, along with subsequent medical and pharmaceutical R&D. This model includes genetic seed development, plant propagation, and cultivation, manufacturing, pharmacological development, medical research, and distribution of the final products to end-users. Our genetic bank contains a verity of strains that are cultivated in our state-of-the-art greenhouses and then processed in post-harvest and manufacturing facilities under GACP and GMP quality standards. The distribution of the final products to end-users is carried out through a global BTB and BTC partner network. MediCane's major markets include Israel, Europe, and Australia. MediCane operates global multi-site pharmaceutical and medical R&D consists of preclinical and clinical trials in various therapeutic areas. MediCane's R&D activities are carried out in-house by its experienced team and through collaboration with world-renowned scientists and leading research institutions, which provide the analytical, biological, and medical expertise. Using a patient-centric approach to clinical trials, MediCane aims to provide potent cannabis-based pharmaceutical products to treat inflammatory and neurological diseases.
1
Source: Federal Office of Statistics Germany (Statistisches Bundesamt)
2
INSIGHT Health - Green Line NPI (Sell in/Pharmacy purchase)
3
Bfarm Companion Survey
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005542/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester’s 2027 Technology And Security Predictions: AI Will Account For 20% Of All Business Technology Spend21.10.2026 10:30:00 CEST | Press release
Technology and security leaders will face mounting pressure to control AI costs, justify infrastructure choices, and manage emerging risks without slowing innovation According to Forrester’s (Nasdaq: FORR) 2027 technology and security predictions, CIOs and CISOs will face growing pressure to realize returns on their AI investments in infrastructure, security, digital sovereignty, and emerging technologies. Additionally, with global technology spending forecasted to reach $6.1 trillion in 2027, technology leaders will need to balance AI governance and control with innovation and business agility. Forrester’s Predictions reports offer forward-looking insights into the trends and signals that empower leaders and their teams to think beyond the conventional and ignite bold ideas for the year ahead. Forrester’s technology and security predictions cover topics including AI, automation and robotics, tech leadership, cloud computing, tech infrastructure and operations, enterprise software, sof
Forrester’s 2027 B2C Marketing, CX, And Digital Predictions: Rising AI Costs Will Force B2C Leaders To Scale Back A Third Of AI Initiatives21.10.2026 10:30:00 CEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 B2C marketing, customer experience, and digital predictions, rising AI costs will force B2C marketing leaders to scale back a third of AI initiatives. As AI usage grows and martech vendors increasingly adopt usage-based pricing models, every agent interaction, generated asset, and automated workflow becomes a billable event. As a result, leaders will need to make tougher decisions and focus investments on AI initiatives that deliver measurable business value. Forrester’s Predictions reports deliver forward-looking insights into the signals and trends that will shape the year ahead. Forrester’s consumer marketing, CX, and digital business predictions cover topics including B2C marketing, customer experience, consumer behavior, digital commerce, media and advertising, marketing agencies, content and creative, and trust and privacy. Additional highlights from Forrester’s 2027 B2C marketing, CX, and digital predictions include:CX staffing will r
LTM Launches BlueVerse™ ValueMesh™ to Help Enterprises Scale AI Across Oracle Transformations21.10.2026 10:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ ValueMesh™, an AI execution fabric designed to help enterprises industrialize AI across the Oracle transformation lifecycle, from strategy and implementation to operations and continuous innovation. BlueVerse™ ValueMesh™ is developed and validated by LTM as part of its Cloud Services expertise. Built on LTM's deep Oracle expertise and BlueVerse™ portfolio, BlueVerse™ ValueMesh™is designed to help enterprises industrialize AI across their Oracle transformation journey. It brings together AI-native delivery, intelligent automation, AI agents, managed services, intelligent business processes, industry solutions, data, and governance in a unified execution model designed to help organizations move beyond fragmented initiatives and isolated pilots and pursue scalable innovation, continuous optimization, and measurable business outcomes across their Oracle estate. At its core, Bl
Forrester’s 2027 B2B Go-To-Market Predictions: AI Agents Will Influence 75% of B2B Purchase Decisions21.10.2026 10:30:00 CEST | Press release
To remain competitive, providers must strengthen customer trust, substantiate value claims, and offer human expertise and guidance According to Forrester’s (Nasdaq: FORR) 2027 B2B go-to-market predictions, business buyers will increasingly deploy AI agents to handle tasks across the buying process, from supplier discovery and information gathering to contract-renewal analysis. While truly autonomous buying will remain concentrated in high-volume, low-risk, and repeatable purchases, the ubiquity of these agents will require providers to ensure that their systems and sellers can respond with speed, accuracy, and consistency. Forrester’s B2B Predictions reports, covering topics including B2B go-to-market strategy, business buyers, and content and creative, offer forward-looking insights to help executives and their teams anticipate change, reduce uncertainty, and make confident decisions ahead of market shifts. Key highlights from the 2027 B2B go-to-market predictions include: Buyers will
Reply Introduces Reply Immersive Experience: a Space Where Artificial Intelligence and Immersive Technologies Bring Multisensory Brand Experiences to Life21.10.2026 10:00:00 CEST | Press release
The first format, AQUA by Christian Mandura, debuts on 21 October 2026 as part of Buonissima in Turin, with a six-act performance combining fine dining, artificial intelligence and storytelling. Reply [EXM, STAR: REY] introduces Reply Immersive Experience, a multisensory smart room that combines artificial intelligence and immersive technologies to create environments where audiences can explore products, interact with digital scenarios and take part in stories that unfold in the space around them. Images, sound, lighting and settings transform in real time, adapting to the experience and audience interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021483868/en/ Reply introduces Reply Immersive Experience, a multisensory smart room that combines artificial intelligence and immersive technologies to create environments where audiences can explore products, interact with digital scenarios and take part in stories t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom